Immune Response Threshold Evaluation for Therapeutic Proteins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting clinically significant antibody responses to therapeutic proteins, such as natalizumab, are inadequate as they often result in false positives and do not account for the clinical significance of the immune response, leading to unnecessary monitoring and potential adverse reactions.
Innovation Solution
A method is developed to identify a clinically significant threshold level of antibody response by evaluating the level of anti-agent antibodies in a control population and setting a threshold at least 2 standard deviations above the mean, ensuring that only responses with significant clinical impact are considered clinically significant, thereby reducing false positives and focusing on meaningful immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a low threshold level (e.g., 5% cutoff) is used to detect immune response, then sensitivity is improved, but false positives increase significantly
Solution Approach 1:
The patent changes the threshold parameter from a conventional low cutoff (5%) to a high cutoff (≥2 standard deviations above mean). This parameter transformation resolves the contradiction by simultaneously achieving both high sensitivity and high reliability, as the elevated threshold is calibrated to distinguish true immune responses from background variability.
Solution Approach 2:
The patent uses a control population to establish a reference distribution of immune response levels. By copying the statistical characteristics (mean and standard deviation) from the control group, the method creates a dynamically adjusted threshold that adapts to population variability, thereby maintaining both sensitivity and reliability across different patient populations.
2Object-affected harmful factors
If monitoring is performed on all patients with detectable immune response, then patient safety is improved, but resource utilization increases due to unnecessary monitoring
Solution Approach 1:
The patent applies different monitoring intensities to different patient subgroups based on their immune response characteristics. Patients with immune responses below the high threshold receive minimal or no monitoring, while only those exceeding the threshold undergo intensive monitoring. This local differentiation optimizes resource allocation while maintaining safety for high-risk patients.
Solution Approach 2:
The patent segments the patient population into distinct risk categories based on the threshold criterion. This segmentation divides patients into 'low-risk' (below threshold) and 'high-risk' (at or above threshold) groups, allowing tailored monitoring strategies that reduce unnecessary resource consumption for low-risk patients while ensuring adequate surveillance for high-risk patients.
3Reliability
If a high threshold level is used to reduce false positives, then reliability is improved, but detection sensitivity decreases
Solution Approach 1:
The patent incorporates feedback from control population data to continuously refine the threshold determination. By using the mean and standard deviation from control subjects, the threshold adapts to population-specific characteristics, ensuring that the high cutoff does not inadvertently reduce sensitivity. This feedback mechanism maintains optimal detection performance while achieving false positive reduction.
Data Source
AI summary
The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).